526 related articles for article (PubMed ID: 28572467)
1. Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort.
Lubrano E; De Socio A; Perrotta FM
J Rheumatol; 2017 Aug; 44(8):1159-1164. PubMed ID: 28572467
[TBL] [Abstract][Full Text] [Related]
2. Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population.
Michelsen B; Diamantopoulos AP; Høiberg HK; Soldal DM; Kavanaugh A; Haugeberg G
J Rheumatol; 2017 Apr; 44(4):431-436. PubMed ID: 28148701
[TBL] [Abstract][Full Text] [Related]
3. What Should Be the Primary Target of "Treat to Target" in Psoriatic Arthritis?
Coates LC; Lubrano E; Perrotta FM; Emery P; Conaghan PG; Helliwell PS
J Rheumatol; 2019 Jan; 46(1):38-42. PubMed ID: 30219765
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Different Remission and Low Disease Definitions in Psoriatic Arthritis and Evaluation of Their Prognostic Value.
Coates LC; Gottlieb AB; Merola JF; Boone C; Szumski A; Chhabra A
J Rheumatol; 2019 Feb; 46(2):160-165. PubMed ID: 30323006
[TBL] [Abstract][Full Text] [Related]
5. Very Low Disease Activity, DAPSA Remission, and Impact of Disease in a Spanish Population with Psoriatic Arthritis.
Queiro R; Cañete JD; Montilla C; Abad MA; Montoro M; Gómez S; Cábez A;
J Rheumatol; 2019 Jul; 46(7):710-715. PubMed ID: 30709957
[TBL] [Abstract][Full Text] [Related]
6. Burden of Psoriatic Arthritis According to Different Definitions of Disease Activity: Comparing Minimal Disease Activity and the Disease Activity Index for Psoriatic Arthritis.
Wervers K; Vis M; Tchetveriko I; Gerards AH; Kok MR; Appels CWY; van der Graaff WL; van Groenendael JHLM; Korswagen LA; Veris-van Dieren JJ; Hazes JMW; Luime JJ
Arthritis Care Res (Hoboken); 2018 Dec; 70(12):1764-1770. PubMed ID: 29609220
[TBL] [Abstract][Full Text] [Related]
7. Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries.
Gorlier C; Orbai AM; Puyraimond-Zemmour D; Coates LC; Kiltz U; Leung YY; Palominos P; Cañete JD; Scrivo R; Balanescu A; Dernis E; Tälli S; Ruyssen-Witrand A; Soubrier M; Aydin SZ; Eder L; Gaydukova I; Lubrano E; Kalyoncu U; Richette P; Husni ME; de Wit M; Smolen JS; Gossec L
Ann Rheum Dis; 2019 Feb; 78(2):201-208. PubMed ID: 30442648
[TBL] [Abstract][Full Text] [Related]
8. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score.
Schoels MM; Aletaha D; Alasti F; Smolen JS
Ann Rheum Dis; 2016 May; 75(5):811-8. PubMed ID: 26269398
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Composite Measure Remission Targets in Psoriatic Arthritis.
Farkas F; Ikumi N; Elmamoun M; Szentpetery A; FitzGerald O
J Rheumatol; 2021 Aug; 48(8):1272-1278. PubMed ID: 33722944
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of minimal disease activity in Australian patients with Psoriatic Arthritis: Assessing the outcome of national funding criteria for biologic disease-modifying antirheumatic drug prescribing.
Pontifex EK; Dissanayake K; Bursill D; Gill T
Int J Rheum Dis; 2019 Feb; 22(2):262-268. PubMed ID: 30450819
[TBL] [Abstract][Full Text] [Related]
11. Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study.
Coates LC; Nash P; Kvien TK; Gossec L; Mease PJ; Rasouliyan L; Pricop L; Jugl SM; Gandhi KK; Gaillez C; Smolen JS
Semin Arthritis Rheum; 2020 Aug; 50(4):709-718. PubMed ID: 32521325
[TBL] [Abstract][Full Text] [Related]
12. Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies.
Schneeberger EE; Citera G; Nash P; Smolen JS; Mease PJ; Soriano ER; Helling C; Szumski AE; Mundayat R; de León DP
Semin Arthritis Rheum; 2023 Feb; 58():152134. PubMed ID: 36476498
[TBL] [Abstract][Full Text] [Related]
13. Patient's Global Assessment as an Outcome Measure for Psoriatic Arthritis in Clinical Practice: A Surrogate for Measuring Low Disease Activity?
Lubrano E; Perrotta FM; Parsons WJ; Marchesoni A
J Rheumatol; 2015 Dec; 42(12):2332-8. PubMed ID: 26523033
[TBL] [Abstract][Full Text] [Related]
14. Ultrasonographic evaluation in psoriatic arthritis is of major importance in evaluating disease activity.
Michelsen B; Diamantopoulos AP; Hammer HB; Soldal DM; Kavanaugh A; Haugeberg G
Ann Rheum Dis; 2016 Dec; 75(12):2108-2113. PubMed ID: 27091837
[TBL] [Abstract][Full Text] [Related]
15. Assessment of Response to Treatment, Remission, and Minimal Disease Activity in Axial Psoriatic Arthritis Treated with Tumor Necrosis Factor Inhibitors.
Lubrano E; Parsons WJ; Perrotta FM
J Rheumatol; 2016 May; 43(5):918-23. PubMed ID: 26980581
[TBL] [Abstract][Full Text] [Related]
16. Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis.
Coates LC; Ritchlin CT; Gossec L; Helliwell PS; Rahman P; Kollmeier AP; Xu XL; Shawi M; Karyekar CS; Contré C; Noël W; Sheng S; Wang Y; Xu S; Mease PJ
Rheumatology (Oxford); 2023 Feb; 62(2):606-616. PubMed ID: 35766811
[TBL] [Abstract][Full Text] [Related]
17. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
Perrotta FM; Marchesoni A; Lubrano E
J Rheumatol; 2016 Feb; 43(2):350-5. PubMed ID: 26669925
[TBL] [Abstract][Full Text] [Related]
18. Minimal disease activity and remission in patients with psoriatic arthritis with elevated body mass index: an observational cohort study in the Swiss Clinical Quality Management cohort.
Vallejo-Yagüe E; Burkard T; Micheroli R; Burden AM
BMJ Open; 2022 Sep; 12(9):e061474. PubMed ID: 36115672
[TBL] [Abstract][Full Text] [Related]
19. Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial.
Helliwell PS; Deodhar A; Gottlieb AB; Boehncke WH; Xu XL; Xu S; Wang Y; Hsia EC; Gladman DD; Ritchlin CT
Arthritis Care Res (Hoboken); 2020 Nov; 72(11):1579-1588. PubMed ID: 31421033
[TBL] [Abstract][Full Text] [Related]
20. Residual symptoms and disease burden among patients with psoriatic arthritis: is a new disease activity index required?
Kilic G; Kilic E; Nas K; Kamanlı A; Tekeoglu İ
Rheumatol Int; 2019 Jan; 39(1):73-81. PubMed ID: 30426235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
